Chicken peptide protein reactant capable of preventing or relieving alcoholic liver injury as well as synthetic peptide and application of chicken peptide protein reactant

By preparing chicken peptide protein reactants through a plastein reaction and adding exogenous amino acids, the problem of insufficient ADH stabilizing activity and antioxidant activity in the existing technology was solved, and the ADH stabilizing activity and antioxidant activity were significantly improved, resulting in better prevention and treatment of alcoholic liver injury.

CN121975893APending Publication Date: 2026-05-05GUANGDONG UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511985757.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-26
Publication Date
2026-05-05

AI Technical Summary

Technical Problem

Existing technologies lack protein and peptide substances that simultaneously possess ADH-stabilizing activity and antioxidant properties, making it difficult to effectively prevent or alleviate alcoholic liver damage.

Method used

Chicken peptides were prepared by performing a plastein reaction on chicken peptides and adding exogenous amino acids to enhance their ADH stabilizing and antioxidant activities. The specific methods included enzymatic hydrolysis, centrifugation, protein-like reaction, and preparation of synthetic peptides.

Benefits of technology

It significantly enhances the ADH stabilizing and antioxidant activities of chicken peptides, enabling better prevention or relief of alcoholic liver damage, and exhibiting better digestive stability and therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121975893A_ABST
    Figure CN121975893A_ABST
Patent Text Reader

Abstract

The invention discloses a chicken peptide protein reactant capable of preventing or relieving alcoholic liver injury as well as a synthetic peptide and an application of the chicken peptide protein reactant. According to the preparation method, protease and tryptophan are added into the chicken enzymolysis product, and enzyme deactivation is performed after proteoid reaction, so that the prepared chicken peptide proteoid reactant has relatively good ADH stable activity and antioxidant activity, and the ADH stable activity and the antioxidant activity are remarkably improved compared with those of the chicken enzymolysis product CP; meanwhile, the digestion stability of the chicken peptide is also improved, and the chicken peptide has a better effect of preventing and treating the alcoholic liver injury. The peptide fragment is further analyzed by mass spectrometry, and six synthetic peptides which are identified and synthesized from chicken peptide protein reactants also have better ADH stable activity and antioxidant activity. More sources and options are provided for protein polypeptide substances with ADH activity and antioxidant activity, the preparation method is simple, convenient and rapid, reaction conditions are mild, and the protein polypeptide can be better used for preparing products for preventing and treating alcoholic liver injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of polypeptide preparation and biomedical technology, specifically to a chicken peptide protein reactant that can prevent or alleviate alcoholic liver damage, its synthetic peptide, and its applications. Background Technology

[0002] Alcohol dehydrogenase (ADH) is a key enzyme in alcohol metabolism, and its activity directly affects the rate of alcohol breakdown and the body's tolerance to alcohol. People with high ADH activity metabolize alcohol quickly, accumulate less acetaldehyde, and have a lower risk of liver and nervous system damage. However, long-term heavy drinking inhibits ADH activity. Current medical interventions, such as the use of hepatoprotective drugs (e.g., silymarin, compound glycyrrhizin), can indirectly increase enzyme activity, thereby improving alcohol metabolism, reducing the burden on the body, and maintaining normal liver function.

[0003] Alcoholic liver injury is closely related to the metabolic capacity of ADH (acetaldehyde dehydrogenase). The core causes of alcoholic liver injury are the direct toxicity of acetaldehyde, oxidative stress and inflammation, and metabolic disorders. Inhibition of ADH activity leads to acetaldehyde accumulation, which in turn interferes with glucose and lipid metabolism, accelerating liver fibrosis. Therefore, activating ADH activity to reduce acetaldehyde accumulation can prevent or alleviate alcoholic liver injury, especially acute alcohol poisoning. Simultaneously, oxidative stress, by generating large amounts of free radicals, damaging cell structure, and inducing inflammation and apoptosis, promotes the activation of hepatic stellate cells, accelerates the fibrotic process, and further damages the liver.

[0004] Existing research has disclosed protein peptides for ADH activation, including chia seed meal protein hydrolysate, corn protein, seaweed (Wakame) protein, and whole sea bass protein hydrolysate. However, most studies focus either on ADH activation activity (e.g., for hangover relief and liver protection) or on antioxidant activity (e.g., for anti-aging and anti-inflammation). Currently, there are few studies and reports on protein peptides that can simultaneously activate ADH (alcohol dehydrogenase) and provide antioxidant benefits. Therefore, to further enhance ADH stabilization and antioxidant activity, there is an urgent need to develop more and more efficient protein peptide products that can better prevent or alleviate alcoholic liver damage. This invention application is therefore proposed. Summary of the Invention

[0005] The technical problem to be solved by the present invention is to overcome the lack of existing substances that simultaneously possess ADH stabilizing activity and antioxidant effects, and to improve the ADH stabilizing activity and antioxidant effects of chicken-derived peptides. The present invention provides a chicken peptide protein reactant that can prevent or alleviate alcoholic liver damage, as well as its synthetic peptide and applications.

[0006] The first objective of this invention is to provide a chicken peptide protein reactant.

[0007] A second objective of this invention is to provide a method for preparing chicken peptide protein reactants.

[0008] A third objective of this invention is to provide the application of chicken peptide protein reactants.

[0009] The fourth object of the present invention is to provide a synthetic peptide.

[0010] A fifth objective of this invention is to provide applications for synthetic peptides.

[0011] The sixth object of this invention is to provide a product.

[0012] The above-mentioned objective of this invention is achieved through the following technical solution: This invention provides a chicken peptide protein reactant, which is obtained by enzymatically hydrolyzing chicken meat with 0.5-2% protease to obtain chicken enzymatic hydrolysate; 0.01-10% protease and 1-10% tryptophan are added to 25-60% of the chicken enzymatic hydrolysate to perform a protein-like reaction, after which the enzyme is inactivated, centrifuged, and the supernatant is obtained.

[0013] This invention utilizes the Plastein reaction to process chicken-derived peptides. The resulting protein-like reactants, prepared by adding exogenous amino acids, exhibit excellent ADH stabilizing and antioxidant activities, significantly enhanced compared to the enzymatic hydrolysis product CP. The ADH stabilizing activity of the chicken peptide protein-like reactants provided by this invention is increased to 134.68±0.64% of CP, the ABTS radical scavenging activity to 241.10±2.95% of CP, and the DPPH radical scavenging activity to 209.64±2.20% of CP. Simultaneously, it improves the digestible stability of chicken peptides, demonstrating better efficacy in preventing and treating alcoholic liver injury, and can be used to alleviate inflammation caused by alcoholic liver injury. Chemical driving force analysis shows that after the Plastein reaction, the hydrogen bonding and hydrophobic interactions of the chicken peptide protein-like reactants increase, while the covalent disulfide bonds and electrostatic interactions decrease, indicating that hydrogen bonding and hydrophobic interactions are the main driving forces for the formation of the Plastein reaction products. Further mass spectrometry analysis revealed significant upregulation of 675 peptides in chicken peptide protein reactant A5-2 compared to CP. Evaluation showed that 64 of these peptides were generated through hydrogen bonding and hydrophobic interactions and exhibited certain bioactivity. The chicken peptide protein reactant provided by this invention possesses both ADH-stabilizing and antioxidant activities. Its preparation method is simple and rapid, and the reaction conditions are mild, making it better suited for preparing products to prevent and treat alcoholic liver injury.

[0014] This invention provides a method for preparing chicken peptide protein reactants. Chicken meat is pulverized and mixed with 3-5 times its volume of distilled water. The pH is adjusted to 7.9-8.1, and 0.5-2% protease is added for enzymatic hydrolysis. After enzyme inactivation, the supernatant is collected after centrifugation to obtain the chicken enzymatic hydrolysate. 0.01-10% protease and 1-10% tryptophan are added to the chicken enzymatic hydrolysate, and the pH is adjusted to 6-11. The mixture is then subjected to hydrolysis with shaking at 15-70℃ for 0.5-72 hours to perform a protein-like reaction. After enzyme inactivation, the mixture is centrifuged, and the supernatant is collected to obtain the final product.

[0015] Preferably, the protease is selected from alkaline protease, neutral protease, or papain.

[0016] More preferably, the first enzymatic hydrolysis is performed using 0.5-2% alkaline protease, and the second plastein reaction is performed using 0.01-10% alkaline protease, neutral protease, or papain.

[0017] More preferably, the plastein-reactive protease is selected from 0.1-5% of alkaline protease, neutral protease, or papain.

[0018] More preferably, the first enzymatic hydrolysis is performed using 0.5% alkaline protease, and the second plastein reaction is performed using 1% alkaline protease, neutral protease, or papain; the hydrolysis conditions are pH 6-10, 40-60℃, and hydrolysis time is 1-10 h.

[0019] Preferably, the enzymatic hydrolysis conditions for different enzymes are: alkaline protease (pH 8, 55℃), papain (pH 7, 55℃), and neutral protease (pH 7, 50℃).

[0020] Preferably, the first enzymatic hydrolysis is performed at 55°C for 6-10 hours; the enzyme is then inactivated in boiling water for 15 minutes, cooled to room temperature, and the hydrolysate is centrifuged at 8000g for 15 minutes at 4°C, and the supernatant is collected.

[0021] Preferably, the concentration of the chicken peptide CP is 25-35%.

[0022] Preferably, the concentration of tryptophan is 1-6%.

[0023] This invention provides the application of chicken peptide protein reactants in the preparation of ADH-activated products and / or antioxidant products.

[0024] This invention provides the application of chicken peptide protein reactants in the preparation of products for preventing or alleviating alcoholic liver damage.

[0025] Further peptide sequence identification and peptidomics analysis were performed on the chicken peptide protein reactants prepared by the above method. 64 peptides significantly different from chicken peptide CP were identified in product A5-2. Six peptides with high activity potential (AAW, WAF, VVWF, YFF, TLW, and WLL) were screened out and synthesized individually. Verification showed that these synthesized peptides exhibited good ADH stabilizing activity and antioxidant properties, and possessed ABTS free radical scavenging ability comparable to or better than that of the antioxidant water-soluble vitamin E (Trolox). This provides more sources and options for protein peptides with both ADH (alcohol dehydrogenase) and antioxidant activities.

[0026] Therefore, the present invention also provides a synthetic peptide, identified from the above-mentioned chicken peptide protein reactants, containing peptide segments: AAW, WAF, VVWF, YFF, TLW, and WLL.

[0027] This invention provides the use of the above-mentioned synthetic peptide in the preparation of ADH-activated products and / or antioxidant products.

[0028] This invention provides an ADH-activating product and / or an antioxidant product containing chicken peptide protein reactants or the above-mentioned synthetic peptides.

[0029] This invention provides the application of the above-mentioned polypeptide in the preparation of ADH-activated products and / or antioxidant products.

[0030] The present invention has the following beneficial effects: This invention provides a chicken peptide protein reactant, its synthetic peptides, and their applications. The protein reactant prepared by performing a plastein reaction on chicken-derived polypeptides and adding exogenous amino acids exhibits good ADH stabilizing and antioxidant activities, significantly improved compared to the ADH stabilizing and antioxidant activities of chicken enzymatic hydrolysate CP. Compared to CP, its ADH stabilizing activity is increased by 134.68±0.64%, its ABTS free radical scavenging activity by 241.10±2.95%, and its DPPH free radical scavenging activity by 209.64±2.20%, while also improving digestive stability and demonstrating better preventative or alleviating effects of alcoholic liver damage. Further mass spectrometry analysis revealed six synthetic peptides isolated and identified from the chicken peptide protein reactant: WAF, VVWF, AAW, YFF, TLW, and WLL, which also exhibit good ADH stabilizing and antioxidant activities. This invention provides more sources and options for protein and polypeptide substances that simultaneously possess ADH activity and antioxidant activity. The preparation method is simple and quick, and the reaction conditions are mild, making it better suited for preparing products that prevent or alleviate alcoholic liver damage. Attached Figure Description

[0031] Figure 1The results of ADH stabilizing activity and antioxidant activity assays are shown in the figure (CP represents chicken peptide; A2, P2, and N2 represent plastein reactants obtained after 2 hours of reaction with alkaline protease, papain, and neutral protease, respectively; A5-2 represents alkaline protease with 5% tryptophan added for 2 hours; P5-2 represents papain with 5% tryptophan added for 2 hours; and N5-2 represents neutral protease with 5% tryptophan added for 2 hours).

[0032] Figure 2 The results are for turbidity and free amino group determination.

[0033] Figure 3 To simulate the digestive results of the stomach and gastrointestinal tract.

[0034] Figure 4 The results are from the chemical driving force analysis.

[0035] Figure 5 The results show the levels of inflammatory factors in a mouse model of alcoholic liver disease.

[0036] Figure 6 The results of peptide intersection are used to assess hydrophobicity, hydrogen bond formation ability, and activity potential.

[0037] Figure 7 Results of ADH stabilizing activity and DPPH free radical scavenging activity of six synthetic peptides. Detailed Implementation

[0038] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but the embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in this technical field.

[0039] Unless otherwise specified, all reagents and materials used in the following examples are commercially available.

[0040] Example 1: Preparation of Plastein reaction products The enzymatic hydrolysate of chicken breast was prepared according to the method disclosed in existing research (Xiao Chuqiao. Preparation of ADH-activated peptide from chicken protein and its protective mechanism against alcoholic liver injury in mice [D]. South China University of Technology, 2020. DOI:10.27151 / d.cnki.ghnlu.2020.000069.). The specific method was as follows: the chicken breast was chopped and then mixed with 5 times the volume of distilled water. The pH was adjusted to 8.0, 0.5% alkaline protease was added, and the mixture was hydrolyzed in a constant temperature shaker at 55℃ for 8 hours. The enzyme was inactivated in boiling water for 15 minutes. After cooling to room temperature, the hydrolysate was centrifuged at 8000g for 15 minutes at 4℃. The supernatant was collected and freeze-dried to prepare chicken peptide (CP) for later use.

[0041] 1% protease (alkaline protease (pH 8, 55℃), papain (pH 7, 55℃), and neutral protease (pH 7, 50℃)) was added to 30% w / v chicken peptide (CP) for reaction. 5% tryptophan was added to adjust the pH. The mixture was hydrolyzed in a constant temperature shaker at 50-55℃ for 2 h. The sample was then incubated in a boiling water bath for 10 min to inactivate the enzyme. After centrifugation at 4℃ and 5000g for 5 min, the supernatant was collected to obtain the plastein reaction product.

[0042] According to the above reaction method, three products were prepared: (1) chicken peptide CP (enzymatic hydrolysis product) without Plastein reaction; (2) chicken peptide combination with Plastein reaction but without tryptophan reaction: A2, P2, N2 (Plastein reaction group of different proteases); (3) chicken peptide combination with Plastein reaction and tryptophan reaction: A5-2, P5-2, N5-2.

[0043] Example 2: Determination of ADH stabilizing activity and antioxidant properties (1) Relative ADH stability assay: 50 μL of sample solution (0.1 mg / mL of the products CP, A2, P2, N2, A5-2, P5-2, N5-2 obtained in Example 1) was mixed with 50 μL of ADH (0.2 U / mL in 10 mM PBS, pH 7.4) and incubated at 37°C for 60 minutes. Then, 150 μL of detection reagent (containing 22.4 mM sodium pyrophosphate, 3.3% ethanol, and 7.8 mM NAD) was added. + The absorbance at 340 nm was recorded every minute for 10 minutes. Ultrapure water was used as a control. The initial reaction rate of unincubated ADH was defined as V0, and the reaction rate of ADH after 60 minutes of incubation was defined as Vs. The relative stable activity of ADH was calculated using the following formula: ADH stable activity = (Vs / V0) × 100%.

[0044] (2) ABTS free radical scavenging activity assay: A 7 mM ABTS stock solution was prepared using 2.45 mM potassium persulfate and stored at 4°C for 16 hours. Before use, the ABTS solution was diluted with 50 mM PBS (pH 7.4) to an absorbance of 0.70 ± 0.02 at 734 nm. In the experiment, 20 μL of sample (0.1 mg / mL, products CP, A2, P2, N2, A5-2, P5-2, N5-2 obtained in Example 1) was mixed with 200 μL of ABTS solution, incubated in the dark for 6 minutes, and the absorbance was measured at 734 nm. PBS and Trolox were used as blank control and positive control, respectively.

[0045] The free radical scavenging rate is calculated using the following formula: ABTS scavenging rate (%) = (absorbance of control group - absorbance of sample) / absorbance of control group × 100%.

[0046] (3) DPPH radical scavenging activity: 30 μL of sample solution (10 mg / mL, products CP, A2, P2, N2, A5-2, P5-2, N5-2 obtained in Example 1) was mixed with 150 μL of ethanol, followed by the addition of 37.5 μL of DPPH ethanol solution (0.02% w / v). After mixing, the reaction was carried out in the dark for 60 minutes, and the absorbance was measured at 517 nm. The control group was prepared by replacing the sample with an equal volume of water.

[0047] DPPH free radical scavenging activity is calculated using the following formula: DPPH free radical scavenging activity (%) = (control absorbance) (Sample absorbance) × 100 / control absorbance.

[0048] The results are as follows Figure 1 As shown, compared with the chicken peptide CP group, A2, P2, and N2 after the plastein reaction can enhance the ADH stabilizing activity and antioxidant activity of its reaction product; while the simultaneous addition of exogenous amino acids A5-2, P5-2, and N5-2 through the plastein reaction can significantly enhance the ADH stabilizing activity and oxidative activity. Among them, compared with CP, A5-2 showed a more significant improvement in relative ADH stabilizing activity (134.68±0.64%), relative ABTS radical scavenging activity (241.10±2.95%), and relative DPPH radical scavenging activity (209.64±2.20%).

[0049] Example 3: Determination of turbidity and free amino groups An increase in turbidity is a typical characteristic of the Plastein reaction. The occurrence of the Plastein reaction and the success of tryptophan linkage can be determined by measuring the turbidity and free amino groups of the Plastein reaction product A5-2.

[0050] Turbidity determination: The sample solutions of A5-2 or CP (100 mg / mL) were allowed to stand at 20 °C for 15 min, vortexed to mix, and the absorbance was measured at 460 nm.

[0051] Determination of free amino groups: Mix 20 μL of A5-2 or CP sample solution (0.3 mg / mL) with 200 μL of OPA reagent, react precisely for 2 min, and then measure the absorbance at 340 nm. Establish a standard curve using serine standards.

[0052] The results are as follows Figure 2As shown, the relative turbidity of A5-2 is significantly higher than that of CP, indicating the occurrence of the plastein reaction. The decrease in free amino groups indicates that free amino groups are covalently linked to chicken peptides, while the significant decrease in the relative free amino groups of A5-2 relative to CP suggests that exogenous tryptophan is covalently linked into chicken peptides.

[0053] Example 4 Digestive stability test Simulated gastric and gastrointestinal digestion employed a two-step pepsin-trypsin digestion model: A5-2 and CP samples were dissolved in ultrapure water (30% w / v) and adjusted to pH 2.0. Pepsin (4%, w / w) was added, and the mixture was incubated at 37°C for 2 hours (gastric stage). Subsequently, the pH was adjusted to 7.5, trypsin (4%, w / w) was added, and the mixture was incubated at 37°C for 2 hours (intestinal stage). Digestion was terminated by a water bath (90°C, 10 minutes). The relative ADH stability, ABTS, and DPPH free radical scavenging activities of the undigested, gastric-digested, and gastrointestinal-digested samples were determined using the method described in Example 3 to assess digestive stability.

[0054] The measurement results are as follows Figure 3 As shown, both before and after simulated gastrointestinal digestion, A5-2 exhibited higher relative ADH stability and antioxidant activity than CP. Furthermore, circular dichroism spectroscopy and Fourier transform infrared spectroscopy revealed an increased β-sheet content, a structure that enhances stability. Therefore, it is hypothesized that the increased β-sheet content, resulting from the plastein reaction leading to peptide aggregation, improves digestive stability.

[0055] Example 5: Chemical Driving Force Analysis A5-2 and CP samples (10% w / v) were dissolved in 0.5 M citrate buffer (pH 3.0), allowed to stand at room temperature for 15 minutes, and then the absorbance was read at 460 nm. To assess the chemical forces in the plastein reaction, the samples were boiled (95 °C, 2 min) to break hydrogen bonds, or the citrate buffer was replaced with sodium dodecyl sulfate (SDS), urea, β-mercaptoethanol, or sodium chloride to assess hydrophobic interactions, hydrogen bonding, covalent disulfide bonding, and electrostatic interactions, respectively.

[0056] The results are as follows Figure 4 As shown, the Plastein reaction results in an increase in hydrogen bonding and hydrophobic interactions of A5-2, while a decrease in covalent disulfide bonds and electrostatic interactions, indicating that hydrogen bonding and hydrophobic interactions are the main driving forces for the formation of the Plastein reaction product A5-2.

[0057] Example 6: The preventive and therapeutic effects of chicken peptide protein products on alcoholic liver injury. The mice used in the experiment were male SPF-grade C57 mice (8 weeks old, weighing 20±2 g, purchased from Guangzhou Mais Biotechnology Co., Ltd.). The mice were cultured under standard conditions with a 12-hour day-night cycle (7:00 to 19:00). Mice had free access to food and tap water, and the ambient temperature was 25±2°C with a relative humidity of 60±5%. All mice were pre-fed for one week to acclimatize to the experimental environment.

[0058] Forty mice were randomly divided into four groups of ten each: (1) Control group, (2) Acute alcohol poisoning model group, (3) Chicken peptide sample group (CP), and (4) Chicken peptide protein sample group (A5-2). The mice were weighed before each experiment to determine the actual amount of sample administered by gavage. Mice in the chicken peptide group and the protein sample group were administered 400 mg / kg of sample by gavage, while mice in the control group and the acute alcohol poisoning model group were administered the same volume of physiological saline. After 30 min, except for the control group, the other three groups of mice were administered 10 g / kg of 56-degree Hongxing Erguotou liquor by gavage to induce acute alcohol poisoning in the mice. Mice in the control group were administered the same volume of physiological saline by gavage. The sample and liquor were administered by gavage once every 24 h for a total of five times to induce acute liver injury in the mice. Blood was collected from the eyeballs of the mice 9 h after the last administration of liquor. The lipopolysaccharide content, tumor necrosis factor α content, and interleukin-6 content of the mice were detected by ELISA kit.

[0059] The measurement results are as follows Figure 5 As shown, mice treated with the drug had fewer inflammatory factors than the alcoholic liver disease model group, indicating a certain therapeutic effect. The closer the levels were to the control group, the better the therapeutic effect. Both CP and A5-2 reduced the levels of inflammatory factors caused by alcoholic liver damage, but A5-2 was more effective than CP, demonstrating better prevention and treatment of alcoholic liver damage and better alleviating inflammation caused by alcoholic liver damage. This suggests that A5-2 has a superior effect in preventing or alleviating alcoholic liver damage compared to CP.

[0060] Example 7 Peptide sequence identification and peptidomics analysis A5-2 and CP were determined by high-resolution UPLC-MS / MS to obtain mass spectrometry data, and then the peptide sequence was identified using MaxQuant v2.7.0.0 software.

[0061] Peptide sequences were identified and quantified using a label-free peptidomics strategy, ultimately identifying 1711 peptides from CP and A5-2 (including common peptide sequences and different peptide sequences). Comparing A5-2 with CP, the fold change (FC) of tryptophan-containing peptides was calculated, showing that A5-2 contained 6.52 times more tryptophan-containing peptides than CP. Of the 1711 peptides, 675 were significantly upregulated in A5-2 compared to CP, representing peptides generated via the plastein reaction. For these 675 upregulated peptides: PeptideRanker was used for scoring, with a score >0.5 indicating potential activity, totaling 202 peptides; log2FC=1 indicates a doubling of activity, and GRAVY was used for hydrophobicity assessment, with a score >0 indicating hydrophobicity, resulting in 245 peptides after screening based on GRAVY≥0 and log2FC≥1; after converting the peptide sequences to Smiles, the number of hydrogen bond donors and acceptors was calculated using RDKit (Lipinski. NumHDonors / NumHAcceptors), and then screened based on a total number of hydrogen bond donors and acceptors ≥10 and log2FC≥1, resulting in 397 peptides.

[0062] After filtering the above three results, the intersection of the peptides yielded 64 peptides, as follows: Figure 6 As shown, these 64 peptides can be considered to be peptides with bioactive potential generated by the Plastein reaction through hydrogen bonding and hydrophobic interactions. Furthermore, based on the activity enhancement effect of Example 3, it is shown that the main peptides that change after the Plastein reaction enhance the effect; therefore, these 64 peptides are bioactive potential peptides.

[0063] Example 8: Analysis and Identification of Synthetic Peptides The 64 peptides screened in Example 7 were used to predict their antioxidant activity using AnOxPP. A score greater than 0.5 was considered to indicate antioxidant potential. These 64 peptides were then molecularly docked with ADH enzyme and keap1 enzyme, respectively, to evaluate their binding affinity to these enzymes. Higher absolute values ​​of binding energy indicated higher ADH stabilizing activity and antioxidant potential, respectively.

[0064] The results identified six peptide sequences with an AnOxPP score greater than 0.5 and ranking among the top six in binding energy: WAF, VVWF, AAW, YFF, TLW, and WLL. Quantitative data for these six peptides are shown in Table 1 (Intensity is obtained through peak area, representing the amount of peptide; a larger value indicates higher content, and a value of 0 indicates the absence of the peptide; in the table, 0 in CP and not 0 in A5-2 indicate newly generated peptides from the protein-like reaction). These sequences are newly generated or have increased content after the Plastein reaction, suggesting that they were formed through hydrogen bonding and hydrophobic interactions driven by the Plastein reaction. Subsequently, these six peptides were synthesized in a solid-phase manner.

[0065] Table 1 Information on newly synthesized peptides

[0066] Example 9: Determination of ADH stabilizing activity and antioxidant activity of synthetic peptides 1. Determination of relative ADH stability activity Each of the six synthetic peptides (identified and synthesized in Example 7) was mixed with 50 μL of ADH (0.2 U / mL in 10 mM PBS, pH 7.4) and incubated at 37°C for 60 minutes. Then, 150 μL of the assay reagent (containing 22.4 mM sodium pyrophosphate, 3.3% ethanol, and 7.8 mM NAD) was added. + The absorbance at 340 nm was recorded every minute for 10 minutes. Ultrapure water was used as a control. The formula for calculating the relative ADH stability activity after the determination was the same as in Example 3.

[0067] 2. Assay of ABTS free radical scavenging activity A 7 mM ABTS stock solution was prepared using 2.45 mM potassium persulfate and stored at 4°C for 16 hours. Before use, the ABTS solution was diluted with 50 mM PBS (pH 7.4) to an absorbance of 0.70 ± 0.02 at 734 nm. In the experiment, 20 μL of the synthetic peptide solution was mixed with 200 μL of ABTS solution, incubated in the dark for 6 minutes, and the absorbance was measured at 734 nm. PBS and Trolox were used as blank and positive controls, respectively. The formula for calculating the free radical scavenging rate was the same as in Example 3.

[0068] A standard curve regression equation was obtained by plotting trolox concentration and ABTS radical scavenging rate using linear fitting. The TEAC value (Trolox equivalent antioxidant capacity) of the synthetic peptide sample was calculated based on the equation and the ABTS radical scavenging rate of the synthetic peptide sample. The results are expressed as μmol TE / μmol synthetic peptide sample.

[0069] 3. DPPH free radical scavenging activity 30 μL of the synthetic peptide solution was mixed with 150 μL of ethanol, followed by the addition of 37.5 μL of DPPH ethanol solution (0.02% w / v). After mixing, the reaction was carried out in the dark for 60 minutes, and the absorbance was measured at 517 nm. The control group was prepared by replacing the sample with an equal volume of water. The formula for calculating the DPPH free radical scavenging activity was the same as in Example 3.

[0070] The results are as follows Figure 7 As shown, the results indicate that these six synthetic peptides enhanced ADH stabilizing activity and DPPH free radical scavenging activity in a dose-dependent manner. Notably, the ABTS free radical scavenging capacity of these six synthetic peptides is comparable to or better than that of the antioxidant Trolox.

[0071] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. A chicken peptide protein reactant, characterized in that, Chicken meat is enzymatically hydrolyzed using 0.5-2% protease to obtain chicken enzymatic hydrolysate; 0.01-10% protease and 1-10% tryptophan are added to 25-60% of the chicken enzymatic hydrolysate to perform a protein-like reaction, thereby inactivating the enzyme, centrifuging, and collecting the supernatant to obtain the final product.

2. The method for preparing the chicken peptide protein reactant according to claim 1, characterized in that, After pulverizing the chicken, add 3-5 times its volume of distilled water and mix. Adjust the pH to 7.9-8.1, add 0.5-2% protease for enzymatic hydrolysis, inactivate the enzyme, centrifuge, and collect the supernatant to obtain the chicken enzymatic hydrolysate. Add 0.01-10% protease and 1-10% tryptophan to the chicken enzymatic hydrolysate, adjust the pH to 6-11, and hydrolyze with shaking at 15-70℃ for 0.5-72 hours. After protein-like reaction, inactivate the enzyme, centrifuge, and collect the supernatant to obtain the final product.

3. The method according to claim 2, characterized in that, The protease is selected from alkaline protease, neutral protease, or papain.

4. The method according to claim 2, characterized in that, The concentration of the protease is 0.1-5%.

5. The method according to claim 2, characterized in that, The concentration of tryptophan is 1-6%.

6. The use of the chicken peptide protein reactant of claim 1 in the preparation of ADH-activated products and / or antioxidant products.

7. The use of the chicken peptide protein reactant of claim 1 in the preparation of products for preventing or alleviating alcoholic liver injury.

8. A synthetic peptide, characterized in that, The following peptides were identified from the chicken peptide protein reactants of claim 1: AAW, WAF, VVWF, YFF, TLW, and WLL.

9. The use of the synthetic peptide of claim 8 in the preparation of ADH-activated products and / or antioxidant products.

10. An ADH activating product and / or an antioxidant product, characterized in that, The chicken peptide protein reactant of claim 1 or the synthetic peptide of claim 8.